GlassScriptPhysician profile
Olivia Bruno
NPI 1881256055
$5,671.47
in general payments reported to CMS, 2019-2025
25 companies · $1,932 in 2025
The $1,932 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $57.15 · 2021: $851 · 2022: $747 · 2023: $994 · 2024: $1,090 · 2025: $1,932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,016.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,051.16 | 2021-2025 | Tecnis Iol, Tecnis Iol, Tecnis Simplicity |
| Glaukos Corporation | $917.11 | 2021-2025 | Photrexa Viscous and Photrexa, Kxl System (Not Refurbished), Ce-Marked Kxla System |
| Abbvie INC. | $876.00 | 2023-2025 | Xen Glaucoma Treatment System, Ozurdex, Durysta |
| Alcon Vision LLC | $509.84 | 2022-2025 | Clareon, Rocklatan, Simbrinza |
| Harrow Eye, LLC | $286.20 | 2024-2025 | Vevye, Iheezo |
| Topcon Healthcare, INC. | $225.56 | 2023-2024 | |
| Sight Sciences, INC. | $178.77 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $177.95 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $173.28 | 2024-2025 | Oxervate |
| Rxsight INC | $167.45 | 2022-2025 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Biotissue Holdings INC. | $166.18 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $159.15 | 2022-2024 | Xiidra |
| Mallinckrodt Hospital Products INC. | $154.03 | 2023-2025 | Acthar |
| Oyster Point Pharma, INC. | $148.39 | 2024-2025 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $100.76 | 2021-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $87.47 | 2022 | |
| Thea Pharma INC. | $68.90 | 2023-2025 | Iyuzeh |
| Amgen INC. | $47.16 | 2024 | Tepezza |
| Ani Pharmaceuticals, INC. | $36.09 | 2025 | Iluvien |
| Eyepoint US, INC. | $32.16 | 2023 | |
| Aerie Pharmaceuticals, INC. | $27.35 | 2021 | |
| Genentech USA, INC. | $22.10 | 2025 | Vabysmo |
| Kala Pharmaceuticals, INC. | $19.74 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Apellis Pharmaceuticals, INC. | $19.27 | 2025 | Syfovre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Bruno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.